BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35320711)

  • 1. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
    DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
    Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of APOBEC3 mutagenesis in human cancer cells.
    Petljak M; Dananberg A; Chu K; Bergstrom EN; Striepen J; von Morgen P; Chen Y; Shah H; Sale JE; Alexandrov LB; Stratton MR; Maciejowski J
    Nature; 2022 Jul; 607(7920):799-807. PubMed ID: 35859169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.
    Green AM; DeWeerd RA; O'Leary DR; Hansen AR; Hayer KE; Kulej K; Dineen AS; Szeto JH; Garcia BA; Weitzman MD
    EMBO Rep; 2021 Sep; 22(9):e52145. PubMed ID: 34347354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3A damages the cellular genome during DNA replication.
    Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
    Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
    Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
    Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
    Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
    Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
    Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
    PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
    Warren CJ; Westrich JA; Doorslaer KV; Pyeon D
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28825669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme cycling contributes to efficient induction of genome mutagenesis by the cytidine deaminase APOBEC3B.
    Adolph MB; Love RP; Feng Y; Chelico L
    Nucleic Acids Res; 2017 Nov; 45(20):11925-11940. PubMed ID: 28981865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA.
    Bergstrom EN; Luebeck J; Petljak M; Khandekar A; Barnes M; Zhang T; Steele CD; Pillay N; Landi MT; Bafna V; Mischel PS; Harris RS; Alexandrov LB
    Nature; 2022 Feb; 602(7897):510-517. PubMed ID: 35140399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring APOBEC3A protein levels in human cancer cells.
    Dananberg A; Maciejowski J
    Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
    Harjes S; Kurup HM; Rieffer AE; Bayarjargal M; Filitcheva J; Su Y; Hale TK; Filichev VV; Harjes E; Harris RS; Jameson GB
    Nat Commun; 2023 Oct; 14(1):6382. PubMed ID: 37821454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
    Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elephant APOBEC3A cytidine deaminase induces massive double-stranded DNA breaks and apoptosis.
    Li X; Caval V; Wain-Hobson S; Vartanian JP
    Sci Rep; 2019 Jan; 9(1):728. PubMed ID: 30679716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
    Sakhtemani R; Senevirathne V; Stewart J; Perera MLW; Pique-Regi R; Lawrence MS; Bhagwat AS
    J Biol Chem; 2019 Oct; 294(41):15037-15051. PubMed ID: 31431505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seven-membered ring nucleobases as inhibitors of human cytidine deaminase and APOBEC3A.
    Kurup HM; Kvach MV; Harjes S; Jameson GB; Harjes E; Filichev VV
    Org Biomol Chem; 2023 Jun; 21(24):5117-5128. PubMed ID: 37282621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
    Caswell D; Swanton C
    Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
    Naumann JA; Argyris PP; Carpenter MA; Gupta HB; Chen Y; Temiz NA; Zhou Y; Durfee C; Proehl J; Koniar BL; Conticello SG; Largaespada DA; Brown WL; Aihara H; Vogel RI; Harris RS
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SMC5/6 complex prevents genotoxicity upon APOBEC3A-mediated replication stress.
    O'Leary DR; Hansen AR; Fingerman DF; Tran T; Harris BR; Hayer KE; Fan J; Chen E; Tennakoon M; DeWeerd RA; Meroni A; Szeto JH; Weitzman MD; Shalem O; Bednarski J; Vindigni A; Zhao X; Green AM
    bioRxiv; 2024 Mar; ():. PubMed ID: 38077016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.